RU2010122982A - Композиции и способы лечения микробных нарушений - Google Patents
Композиции и способы лечения микробных нарушений Download PDFInfo
- Publication number
- RU2010122982A RU2010122982A RU2010122982/10A RU2010122982A RU2010122982A RU 2010122982 A RU2010122982 A RU 2010122982A RU 2010122982/10 A RU2010122982/10 A RU 2010122982/10A RU 2010122982 A RU2010122982 A RU 2010122982A RU 2010122982 A RU2010122982 A RU 2010122982A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- reg
- specified
- subject
- microbial
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 37
- 230000000813 microbial effect Effects 0.000 title claims abstract 9
- 239000000203 mixture Substances 0.000 title 1
- 230000000845 anti-microbial effect Effects 0.000 claims abstract 17
- 239000004599 antimicrobial Substances 0.000 claims abstract 15
- 229920001184 polypeptide Polymers 0.000 claims abstract 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 15
- 244000000010 microbial pathogen Species 0.000 claims abstract 12
- 241000894006 Bacteria Species 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 208000035475 disorder Diseases 0.000 claims abstract 8
- 208000015181 infectious disease Diseases 0.000 claims abstract 7
- 102100037886 Regenerating islet-derived protein 3-gamma Human genes 0.000 claims abstract 6
- 101001096072 Homo sapiens Regenerating islet-derived protein 3-gamma Proteins 0.000 claims abstract 5
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract 5
- 230000000694 effects Effects 0.000 claims abstract 5
- 230000028993 immune response Effects 0.000 claims abstract 5
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract 4
- 208000011231 Crohn disease Diseases 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims 8
- 241000588724 Escherichia coli Species 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 230000000369 enteropathogenic effect Effects 0.000 claims 2
- 238000009499 grossing Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims 1
- 101710086144 Regenerating islet-derived protein 3-gamma Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
1. Способ лечения инфекции микробным патогеном у субъекта путем модулирования противомикробного иммунного ответа у указанного субъекта, включающий введение указанному субъекту эффективного количества противомикробного полипептида (AMP), где указанным AMP является IL-22. ! 2. Способ лечения инфекции микробным патогеном у субъекта путем модулирования противомикробного иммунного ответа у указанного субъекта, включающий введение указанному субъекту эффективного количества противомикробного полипептида (AMP) или его модулятора, где указанный AMP выбран из группы, состоящей из: IL-6, IL-18, IL-23, REG Iα, REG Iβ, HIP/PAP, REG III, REG IV, Reg-связанной последовательности (RS) и LT. ! 3. Способ модулирования активности противомикробного полипептида (AMP) в клетках субъекта, инфицированного микробным патогеном, включающий приведение указанных клеток в контакт с выделенным AMP, где указанным AMP является IL-22. ! 4. Способ модулирования активности противомикробного полипептида (AMP) в клетках субъекта, инфицированного микробным патогеном, включающий приведение указанных клеток в контакт с выделенным AMP, где указанный AMP выбран из группы, состоящей из IL-6, IL-18, IL-23, REG Iα, REG Iβ, IIIP/PAP, REG III, REG IV, Reg-связанной последовательности (RS) и LT. ! 5. Способ по п.1, где указанная инфекция представляет собой микробное нарушение. ! 6. Способ по п.5, где указанное микробное нарушение представляет собой воспалительное заболевание кишечника (IBD). ! 7. Способ по п.5, где указанное микробное нарушение представляет собой болезнь Крона или язвенный колит (UC). ! 8. Способ по п.1, где указанным микробным патогеном является бактерия. ! 9. Способ по п.8, где указанная бактерия является грамотрицательной. !10
Claims (29)
1. Способ лечения инфекции микробным патогеном у субъекта путем модулирования противомикробного иммунного ответа у указанного субъекта, включающий введение указанному субъекту эффективного количества противомикробного полипептида (AMP), где указанным AMP является IL-22.
2. Способ лечения инфекции микробным патогеном у субъекта путем модулирования противомикробного иммунного ответа у указанного субъекта, включающий введение указанному субъекту эффективного количества противомикробного полипептида (AMP) или его модулятора, где указанный AMP выбран из группы, состоящей из: IL-6, IL-18, IL-23, REG Iα, REG Iβ, HIP/PAP, REG III, REG IV, Reg-связанной последовательности (RS) и LT.
3. Способ модулирования активности противомикробного полипептида (AMP) в клетках субъекта, инфицированного микробным патогеном, включающий приведение указанных клеток в контакт с выделенным AMP, где указанным AMP является IL-22.
4. Способ модулирования активности противомикробного полипептида (AMP) в клетках субъекта, инфицированного микробным патогеном, включающий приведение указанных клеток в контакт с выделенным AMP, где указанный AMP выбран из группы, состоящей из IL-6, IL-18, IL-23, REG Iα, REG Iβ, IIIP/PAP, REG III, REG IV, Reg-связанной последовательности (RS) и LT.
5. Способ по п.1, где указанная инфекция представляет собой микробное нарушение.
6. Способ по п.5, где указанное микробное нарушение представляет собой воспалительное заболевание кишечника (IBD).
7. Способ по п.5, где указанное микробное нарушение представляет собой болезнь Крона или язвенный колит (UC).
8. Способ по п.1, где указанным микробным патогеном является бактерия.
9. Способ по п.8, где указанная бактерия является грамотрицательной.
10. Способ по п.8, где указанная бактерия является грамположительной.
11. Способ по п.8, где указанная бактерия представляет собой бактерию с механизмом прикрепления или сглаживания (A/E).
12. Способ по п.11, где указанная бактерия с механизмом прикрепления или сглаживания (A/E) представляет собой энтерогеморрагическую Escherichia coli (EHEC) и энтеропатогенную E.coli (EPEC).
13. Способ по п.12, где указанная энтеропатогенная E.coli (EHEC) представляет собой E.coli 0157:H7 или E.coli 055:Н7.
14. Способ по п.2, где указанный противомикробный полипептид (AMP) представляет собой RegIIIβ и RegIIIγ.
15. Способ по п.1, где указанным микробным патогеном является вирус.
16. Способ лечения инфекции микробным патогеном у субъекта путем модулирования противомикробного иммунного ответа у указанного субъекта, включающий введение указанному субъекту эффективного количества модулятора противомикробного полипептида (AMP), где указанным модулятором AMP является агонист IL-22.
17. Способ по п.16, где указанный агонист повышает экспрессию и/или активность указанного IL-22.
18. Способ по п.16, где указанным агонистом является полипептид или молекула нуклеиновой кислоты.
19. Способ по п.16, где указанным агонистом является слитый полипептид.
20. Способ по п.16, где указанным агонистом является слитый полипептид Fc.
21. Способ по п.16, где указанным агонистом является антитело или его биологически активный фрагмент.
22. Способ по п.16, где указанным агонистом является моноклональное антитело.
23. Способ по п.16, где указанным агонистом является гуманизированное антитело.
24. Способ по п.1 или 3, где аминокислотная последовательность указанного IL-22 содержит последовательность, представленную в качестве SEQ ID NO: 8.
25. Способ по п.2 или 4, где аминокислотная последовательность указанного AMP содержит последовательность, выбранную из группы аминокислотных последовательностей, состоящей из SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 50 и SEQ ID NO: 52.
26. Способ по п.1 или 3, где последовательность нуклеиновой кислоты, кодирующая указанный IL-22, представляет собой последовательность, представленную в качестве SEQ ID NO: 7.
27. Способ по п.1 или 3, где последовательность нуклеиновой кислоты, кодирующая указанный AMP, содержит последовательность, выбранную из группы последовательностей нуклеиновых кислот, состоящей из SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 49 и SEQ ID NO: 51.
28. Набор, содержащий фармацевтическую композицию для лечения микробного нарушения, где указанная фармацевтическая композиция содержит противомикробный полипептид (AMP), где указанным AMP является IL-22.
29. Набор, содержащий одну или более фармацевтических композиций для лечения микробного нарушения, где каждая из указанных фармацевтических композиций содержит отличающийся противомикробный полипептид (AMP) или его модулятор, и где указанный AMP выбран из группы, состоящей из: IL-6, IL-18, IL-23, REG Iα, REG Iβ, HIP/PAP, REG III, REG IV, Reg-связанной последовательности (RS) и LT.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98617007P | 2007-11-07 | 2007-11-07 | |
| US60/986,170 | 2007-11-07 | ||
| US1362007P | 2007-12-13 | 2007-12-13 | |
| US61/013,620 | 2007-12-13 | ||
| US1562007P | 2007-12-20 | 2007-12-20 | |
| US61/015,620 | 2007-12-20 | ||
| PCT/US2008/082890 WO2009062102A2 (en) | 2007-11-07 | 2008-11-07 | Compositions and methods for treatment of microbial disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010122982A true RU2010122982A (ru) | 2011-12-20 |
| RU2503460C2 RU2503460C2 (ru) | 2014-01-10 |
Family
ID=40551983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010122982/10A RU2503460C2 (ru) | 2007-11-07 | 2008-11-07 | Применение противомикробного полипептида для лечения микробных нарушений |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20090202475A1 (ru) |
| EP (3) | EP2217263A2 (ru) |
| JP (3) | JP5985150B2 (ru) |
| KR (2) | KR101867606B1 (ru) |
| CN (5) | CN104888193A (ru) |
| AU (1) | AU2008323770B2 (ru) |
| CA (1) | CA2705007A1 (ru) |
| CO (1) | CO6280406A2 (ru) |
| DK (1) | DK2514436T3 (ru) |
| ES (1) | ES2662845T3 (ru) |
| HK (2) | HK1214137A1 (ru) |
| HR (1) | HRP20180445T1 (ru) |
| HU (1) | HUE038588T2 (ru) |
| IL (2) | IL205623A0 (ru) |
| LT (1) | LT2514436T (ru) |
| MX (1) | MX2010005108A (ru) |
| NO (1) | NO2514436T3 (ru) |
| PH (1) | PH12013501074A1 (ru) |
| PL (1) | PL2514436T3 (ru) |
| PT (1) | PT2514436T (ru) |
| RS (1) | RS57021B1 (ru) |
| RU (1) | RU2503460C2 (ru) |
| SG (2) | SG10202007210RA (ru) |
| SI (1) | SI2514436T1 (ru) |
| WO (1) | WO2009062102A2 (ru) |
| ZA (1) | ZA201003113B (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| CA2741566A1 (en) * | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| WO2011046616A2 (en) * | 2009-10-15 | 2011-04-21 | New York University | Methods for modulating bacterial infection |
| WO2011127344A2 (en) * | 2010-04-08 | 2011-10-13 | University Of Virginia Patent Foundation | Method to detect and treat infectious or inflammatory diarrhea |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| CA2842969C (en) | 2011-07-25 | 2018-03-27 | Generon (Shanghai) Corporation Ltd. | Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases |
| WO2013085715A1 (en) * | 2011-12-05 | 2013-06-13 | The Trustees Of The University Of Pennsylvania | Graphene-biomolecule bioelectronic devices |
| CN102559759A (zh) * | 2011-12-19 | 2012-07-11 | 西安交通大学医学院第一附属医院 | Hip/pap重组腺病毒及其抗溃疡性结肠炎的应用 |
| CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术（上海）有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
| KR101431324B1 (ko) * | 2012-08-20 | 2014-08-20 | 성균관대학교산학협력단 | ＷＫＹＭＶｍ 펩티드를 포함하는 염증성 장질환 예방 또는 치료용 약학적 조성물 |
| US9314504B2 (en) * | 2013-03-14 | 2016-04-19 | Taipei Medical University | Use of members of IL-10 cytokine family |
| TR201809571T4 (tr) * | 2013-03-15 | 2018-07-23 | Hoffmann La Roche | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. |
| WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| WO2015054386A1 (en) * | 2013-10-08 | 2015-04-16 | Georgia State University Research Foundation, Inc | Compositions including il-18 and il-22 and their use in anti-viral therapies |
| CN103554267A (zh) * | 2013-10-15 | 2014-02-05 | 山西农业大学 | 一种具有抗菌功能的融合蛋白及其构建方法和应用 |
| JP5515104B1 (ja) * | 2013-10-25 | 2014-06-11 | 独立行政法人農業・食品産業技術総合研究機構 | 抗酸菌の増殖促進剤、これを添加して培養する抗酸菌の培養方法、及び、これを含有する抗酸菌の培養用培地 |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| AU2014346554B2 (en) | 2013-11-07 | 2020-06-04 | Evive Biotechnology (Shanghai) Ltd | Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease |
| CN109206484B (zh) * | 2015-11-20 | 2021-06-18 | 深圳市南山区人民医院 | 一种用于预防和治疗肠致病大肠杆菌感染的肽段 |
| CN109328069B (zh) | 2016-04-15 | 2023-09-01 | 亿一生物医药开发(上海)有限公司 | Il-22在治疗坏死性小肠结肠炎中的用途 |
| EP4137509A1 (en) * | 2016-05-18 | 2023-02-22 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| CA3070182A1 (en) * | 2017-07-13 | 2019-01-17 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Reg3alpha for use in the protection of oxygen sensitive gram-positive bacteria |
| WO2022192419A2 (en) | 2021-03-09 | 2022-09-15 | Massachusetts Institute Of Technology | Methods of treating inflammatory bowel disease (ibd) with anti- tnf-blockade |
| CN113304247B (zh) * | 2021-04-01 | 2024-03-19 | 上海市儿科医学研究所 | Reg4蛋白及其在抵抗肠炎伤寒沙门氏菌感染中的应用 |
| CN114409758A (zh) * | 2022-01-24 | 2022-04-29 | 上海市儿科医学研究所 | Reg4抗菌肽治疗致病性大肠埃希菌感染的应用 |
| CN114344451B (zh) * | 2022-01-25 | 2023-09-26 | 上海市肺科医院 | Reg4抗菌肽治疗铜绿假单胞菌感染性肺炎的应用 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR0184860B1 (ko) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법) |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0498843B1 (en) | 1989-10-24 | 1996-06-12 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| CA2086264C (en) | 1990-06-27 | 2002-12-24 | Jeffrey L. Browning | Surface complexed lymphotoxin |
| JPH06500011A (ja) | 1990-06-29 | 1994-01-06 | ラージ スケール バイオロジー コーポレイション | 形質転換された微生物によるメラニンの製造 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| WO1992009300A1 (en) | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
| US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
| DK1500329T3 (da) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Humane antistoffer, der specifikt binder TNF-alfa |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| CA2329274A1 (en) * | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| WO2000039585A1 (en) | 1998-12-28 | 2000-07-06 | Sunesis Pharmaceuticals, Inc. | Identifying small organic molecule ligands for binding |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING A POLYPEPTIDE |
| US20030170823A1 (en) * | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| GB0024442D0 (en) * | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| FR2833011B1 (fr) * | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| AU2003234706A1 (en) | 2002-04-15 | 2003-11-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| WO2004003144A2 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
| AU2003301059A1 (en) * | 2002-12-18 | 2004-07-22 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| RU2006101702A (ru) * | 2003-06-23 | 2006-09-10 | Дженетикс Инститьют, Ллс (Us) | Антитела против интерлейкина-22 и их применения |
| EP2481287B1 (en) * | 2003-08-01 | 2016-07-20 | Stratatech Corporation | Human skin equivalents expressing exogenous polypeptides |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
| EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| US20050277593A1 (en) * | 2004-05-24 | 2005-12-15 | Washington University | Therapeutic uses of Reg protein |
| RU2302460C1 (ru) * | 2005-11-02 | 2007-07-10 | Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBi101-IL18, КОДИРУЮЩАЯ СИНТЕЗ ИНТЕРЛЕЙКИНА-18 ЧЕЛОВЕКА В ТРАНСГЕННЫХ РАСТЕНИЯХ |
| EP2029171A1 (en) * | 2006-06-19 | 2009-03-04 | Wyeth a Corporation of the State of Delaware | Methods of modulating il-22 and il-17 |
-
2008
- 2008-11-07 SI SI200831926T patent/SI2514436T1/en unknown
- 2008-11-07 LT LTEP12169572.0T patent/LT2514436T/lt unknown
- 2008-11-07 HU HUE12169572A patent/HUE038588T2/hu unknown
- 2008-11-07 CN CN201510262894.6A patent/CN104888193A/zh active Pending
- 2008-11-07 KR KR1020107012426A patent/KR101867606B1/ko active IP Right Grant
- 2008-11-07 RS RS20180324A patent/RS57021B1/sr unknown
- 2008-11-07 RU RU2010122982/10A patent/RU2503460C2/ru active
- 2008-11-07 CN CN2013100500120A patent/CN103142999A/zh active Pending
- 2008-11-07 SG SG10202007210RA patent/SG10202007210RA/en unknown
- 2008-11-07 NO NO12169572A patent/NO2514436T3/no unknown
- 2008-11-07 EP EP08848478A patent/EP2217263A2/en not_active Withdrawn
- 2008-11-07 WO PCT/US2008/082890 patent/WO2009062102A2/en active Application Filing
- 2008-11-07 EP EP12169572.0A patent/EP2514436B1/en active Active
- 2008-11-07 CN CN2011101151819A patent/CN102172395A/zh active Pending
- 2008-11-07 SG SG2012082434A patent/SG185972A1/en unknown
- 2008-11-07 MX MX2010005108A patent/MX2010005108A/es active IP Right Grant
- 2008-11-07 CA CA2705007A patent/CA2705007A1/en not_active Abandoned
- 2008-11-07 CN CN201811093788.XA patent/CN108815508A/zh active Pending
- 2008-11-07 DK DK12169572.0T patent/DK2514436T3/en active
- 2008-11-07 EP EP17208162.2A patent/EP3360567A1/en not_active Withdrawn
- 2008-11-07 PT PT121695720T patent/PT2514436T/pt unknown
- 2008-11-07 JP JP2010533299A patent/JP5985150B2/ja active Active
- 2008-11-07 ES ES12169572.0T patent/ES2662845T3/es active Active
- 2008-11-07 KR KR1020167030030A patent/KR20160129099A/ko not_active Application Discontinuation
- 2008-11-07 AU AU2008323770A patent/AU2008323770B2/en not_active Ceased
- 2008-11-07 CN CN2008801241737A patent/CN101951945A/zh active Pending
- 2008-11-07 PL PL12169572T patent/PL2514436T3/pl unknown
- 2008-11-07 US US12/291,380 patent/US20090202475A1/en not_active Abandoned
-
2010
- 2010-05-04 ZA ZA2010/03113A patent/ZA201003113B/en unknown
- 2010-05-09 IL IL205623A patent/IL205623A0/en unknown
- 2010-05-26 CO CO10063303A patent/CO6280406A2/es not_active Application Discontinuation
-
2011
- 2011-05-20 US US13/112,850 patent/US20110280828A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/566,760 patent/US20130052159A1/en not_active Abandoned
-
2013
- 2013-05-27 PH PH12013501074A patent/PH12013501074A1/en unknown
-
2014
- 2014-09-30 JP JP2014200490A patent/JP6266486B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 HK HK16102060.3A patent/HK1214137A1/zh unknown
- 2016-03-09 JP JP2016045739A patent/JP2016117760A/ja active Pending
-
2018
- 2018-03-15 HR HRP20180445TT patent/HRP20180445T1/hr unknown
- 2018-04-16 IL IL258730A patent/IL258730A/en unknown
-
2019
- 2019-01-29 HK HK19101602.7A patent/HK1259102A1/zh unknown
-
2021
- 2021-01-29 US US17/162,924 patent/US20210338778A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010122982A (ru) | Композиции и способы лечения микробных нарушений | |
| Hu et al. | OmpA is a virulence factor of Riemerella anatipestifer | |
| JP2011503102A5 (ru) | ||
| Kaper et al. | Overview and historical perspectives | |
| Wu et al. | Outer membrane protein OmpW of Escherichia coli is required for resistance to phagocytosis | |
| Alteri et al. | Mucosal immunization with iron receptor antigens protects against urinary tract infection | |
| Mason et al. | The non‐typeable Haemophilus influenzae Sap transporter provides a mechanism of antimicrobial peptide resistance and SapD‐dependent potassium acquisition | |
| Abdelhamed et al. | Evaluation of three recombinant outer membrane proteins, OmpA1, Tdr, and TbpA, as potential vaccine antigens against virulent Aeromonas hydrophila infection in channel catfish (Ictalurus punctatus) | |
| Schellhorn | Elucidating the function of the RpoS regulon | |
| Moeck et al. | Characterization of in vitro interactions between a truncated TonB protein from Escherichia coli and the outer membrane receptors FhuA and FepA | |
| Lundberg et al. | Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae | |
| JP2009527226A5 (ru) | ||
| Clegg et al. | More than one way to control hair growth: regulatory mechanisms in enterobacteria that affect fimbriae assembled by the chaperone/usher pathway | |
| Kurabayashi et al. | Fur represses adhesion to, invasion of, and intracellular bacterial community formation within bladder epithelial cells and motility in uropathogenic Escherichia coli | |
| Zhao et al. | Analysis of virulence and immunogenic factors in Aeromonas hydrophila: Towards the development of live vaccines | |
| Esmaeilkhani et al. | In vivo validation of the immunogenicity of recombinant baumannii acinetobactin utilization a protein (rBauA) | |
| Kumar et al. | Structural analysis and cross-protective efficacy of recombinant 87 kDa outer membrane protein (Omp87) of Pasteurella multocida serogroup B: 2 | |
| Ramezanalizadeh et al. | Protective response against Acinetobacter baumannii with ferric iron receptors HemTR-BauA in a murine sepsis model | |
| LaFrentz et al. | Identification of immunogenic proteins within distinct molecular mass fractions of Flavobacterium psychrophilum | |
| Zhang et al. | Immunization with H7-HCP-tir-intimin significantly reduces colonization and shedding of Escherichia coli O157: H7 in goats | |
| Gelfat et al. | Single domain antibodies against enteric pathogen virulence factors are active as curli fiber fusions on probiotic E. coli Nissle 1917 | |
| Sharma et al. | Immune response characterization and vaccine potential of a recombinant chimera comprising B-cell epitope of Aeromonas hydrophila outer membrane protein C and LTB | |
| Bi et al. | Identification and pathogenicity of emerging fish pathogen Acinetobacter johnsonii from a disease outbreak in rainbow trout (Oncorhynchus mykiss) | |
| Cao et al. | Targeting the gram-negative bacteria peptidoglycan synthase MraY as a new approach for monoclonal antibody anti-bacterial activity | |
| Choe et al. | Edwardsiella piscicida lacking the cyclic AMP receptor protein (Crp) is avirulent and immunogenic in fish |